Development of Agents Targeting the TGF-β/Smad System in IBD

In the field of immunity, transformative growth factor beta (known as TGF-β) a type of cytokine is responsible, for controlling the development, specialization and operation of both non immune cells. It contributes to reducing inflammation caused by antigens, within the gut and promoting tolerance. Issues, with TGF beta signaling have been linked to causing inflammation in research studies and various human conditions like bowel disease (IBD). Therapies that can help restore TGF-β signaling are seen as treatments for IBD.

Fig. 1. TGF-β sources and TGF-β targets in IBD. (Ihara, et al., 2017)

Our Services

Ace Therapeutics is a research organization specializing in IBD, dedicated to pushing forward IBD research through a wide range of services aimed at assisting clients in creating innovative treatment approaches that target the TGF β/Smad system in IBD effectively. We provide a variety of studies and preclinical drug development services to aid our clients IBD research efforts at stages.

Analysis of the TGF-β Signaling Pathway in IBD

We investigate the role of TGF-β in IBD, focusing on TGF-β production, signaling, and functions by murine experimental models. Our goal is to enhance our clients' understanding of the role of TGF-β signaling in IBD and to identify novel therapeutic targets associated with TGF-β signaling.

• We can analyze the role of TGF-β1 in antigen-presenting cells and its impact on T-cell activation through a mouse model deficient in TGF-β1.
• The role of Smad7 in IBD can be evaluated using several approaches. This included treating IBD lamina propria mononuclear cells (LPMC) and mucosal explants with a specific Smad7 antisense oligonucleotide (AS). Additionally, the levels of arylhydrocarbon receptor (AhR) can be analyzed in T cells derived from Smad7 transgenic mice.

Development of Agents Targeting the TGF-β Signaling Pathway

Ace Therapeutics is committed to developing drugs that target the TGF-β signaling pathway in IBD. We have extensive animal models of colitis to evaluate the safety and efficacy of these drug candidates. The types of drugs we can develop include:

• Smad7 antisense oligonucleotide-based therapies
• Therapies that influence the microbiota to modulate intestinal TGF-β production
• Therapies that target TGF-β-related adhesion molecules

Ace Therapeutics supports clients in elaborating the role of the TGF-β/Smad system in IBD pathogenesis, and develop TGF-β/Smad-targeted drugs for IBD therapy. If you have questions on our services, or are interested in collaborating, please feel free to contact us. Ace Therapeutics will give every effort to facilitate IBD therapy development for you.